Kalorama projects 8% annual growth for telemedicine market
ROCKVILLE, Md. — Market researcher Kalorama Information recently shared in a New York Times report that the telemedicine market holds significant growth potenital.
"Telemedicine is a $9.2 billion business," stated Kalorama publisher Bruce Carlson in the story. "The field is growing at 8% annually, nearly three times as fast as other medical devices."
The Times article, "Heart and Asthma Monitors? There's an App for That," used information from Kalorama Information's Remote Patient Monitoring Markets Remote Patient Monitoring & Telemedicine Market.
Kalorama Information noted that the market for telemonitoring is growing as awareness of the benefits of the technology increases. And while it's still difficult to get payors to reimburse for every use of the technology, providers themselves are often paying for the equipment as it benefits their operations.
"It's in everyone's interest to cut hospital days," Carlson said. "And with nurse staff shortages in most U.S. regional markets, these technologies make sense for the provider even where unreimbursed. That being said, companies will want to obtain positive studies demonstrating benefits to improve their clout with payors."
The article covered a company named Eko Devices, one of many telehealth companies that has seen investor interest. The company, according to the article, raised nearly $5 million and sold 6,000 digital stethoscopes, used in 700 hospitals. They are marketing the Duo, a digital stethoscope for home use, which could change how heart patients are monitored, the entrepreneurs say. It is scheduled to become available by prescription in the fall. The product, the article said, combines electrocardiogram, or E.K.G., readings and heart sounds into a device that allows patients to monitor their health at home and send data to their physicians.
APhA provides new pharmacist leadership opportunities
WASHINGTON — The American Pharmacists Association on Thursday announced a new Leadership360 Institute that provides pharmacists with opportunities to reach full leadership potential while developing management skills necessary across pharmacy settings.
Institute participants can take part in any or all of the three Leadership tracks including: Lead360, Mentor360, and Manage360. Each track will offer programs to help pharmacists excel in their individual growth, purposeful development and interactions with others.
"APhA is excited to offer a program that can help so many pharmacists enhance their career through our new Leadership360 Institute," stated Thomas Menighan, EVP and CEO of APhA. "Pharmacists have the knowledge and skills to provide excellent patient care services. APhA's new program will help pharmacists develop their skills as leaders on their healthcare teams, in pharmacy, and in their communities."
The Lead360 track launches with the Leader Within program that empowers participants to explore their values, interests, strengths and needs as they take a purposeful approach to life and leadership. The inaugural track starts with live programs in October to kick off American Pharmacists Month and participants can extend the experience through a three-month Virtual Experience.
The Mentor360 track offers pharmacists the opportunity to connect with leaders in the profession in two meaningful, yet different environments: Professional Connections and Practice Collaboratives. Mentor360: Professional Connections is APhA's one-on-one mentor program for pharmacists that pairs individuals seeking to learn more about key pharmacy interest areas with others who have identified those same topics as areas of expertise.
Mentor 360: Practice Collaboratives is APhA's small group-based mentor program that will bring pharmacists together to fuel innovation and progress toward advancing pharmacy practice. Each Practice Collaborative will include a panel of experts who share their knowledge on a defined topic area with a small group of participants through webinars and an exclusive online forum. The Mentor360 programs will launch in early September and is available for APhA's pharmacist members only.
And the Manage360 track will include online management training sessions that provide pharmacists with the skills and tactics they need to effectively manage staff, their practice setting, and themselves. Manage360 will launch in early 2018.
Mylan launches 3 HIV generics in Canada
HERTFORDSHIRE, England, PITTSBURGH and TORONTO — Mylan has launched three generics for treating HIV in Canada. Among the three launches is the company’s generic of Gilead’s Truvada (emtricitabine/tenofovir disoproxil fumarate, 200 mg/300 mg), as well as generics of Atripla (efavirenz, emtricitabine and tenofovir disoproxil fumarate, 600 mg/200 mg/300 mg) and Viread (tenofovir disoproxil, 300 mg).
“Mylan has a strong and sustained commitment to expanding access to treatment for HIV/AIDS and other diseases around the world, and today marks another milestone in those efforts,” Mylan chief commercial officer Tony Mauro said. “More than 40% of people worldwide being treated for HIV/AIDS with an antiretroviral depend on a Mylan product every day, and we're proud to further expand access to such medicines in Canada.”
Mylan has invested $250 million in expanding its antiretroviral production capabilities, enabling it to produce 4 billion antiretroviral tablets and capsules each year, the company said.